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D. Olde Weghuis, R. F. Suijkerbuijk, E. van den Berg, 
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INTRODUCTION
M any different neoplasm s may arise from the various cell 
types that are present in  hum an supportive tissues. The 
term  “soft tissue tum or” is used to denote a subgroup of 
these neoplasms an d  includes synovial sarcomas, fibrosar­
comas, liposarcom as, leiomyosarcomas, rhabdom yosarco­
mas, angiosarcomas, and  the most com m on form, 
malignant fibrous histiocytom as [1]. Cytogenetic studies 
have revealed the occurrence of both  num erical and struc­
tural abnormalities in  several of these tum ors, including  
recurrent chromosomal trans locations [2-5]. in  other soft 
tissue tumors, double m inutes, ring chromosomes, and  
large rod-shaped m arkers have repeatedly been encoun­
tered. These latter anom alies appear to be associated w ith  
gene amplifications [6-8]. Also, osteosarcomas originate 
from supportive tissues [9]. At present, little is know n 
about the cytogenetic alterations that occur in  these 
tum ors or how  such alterations may relate to tum or in itia­
tion and/or progression [2]. However, some studies have 
revealed highly aneuplo id  and extremely com plex karyo­
types w ith num erous cytogenetic abnorm alities including, 
again, supernum erary ring chromosomes and double m in ­
utes [10-12]. Here, on the occasion of Dr. Avery Sand­
berg’s 75th birthday, the recent m olecular genetic analysis 
of a soft tissue tum or (synovial sarcoma)-associated chro­
mosomal translocation and  the delineation via com para­
tive genomic hybridization of more com plex cytogenetic 
anomalies in several other (sub) types of hum an bone and 
soft tissue tumors axe discussed.
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MOLECULAR GENETIC ANALYSIS OF 
t (X ;1 8 )(p ll.2 ;q ll.2 )  IN  HUM AN SYNOVIAL SARCOMAS
Synovial sarcoma is a soft tissue tumor that predom i­
nantly  afflicts adolescents and young adults [1]. Despite 
their designation, it is now  generally accepted that these 
tumors m ay not originate from synovial tissue but, instead, 
from m ultipotent stem  cells that are capable of differentiat­
ing into m esenchym al and/or epithelial structures [1, 13]. 
Furtherm ore, in  spite of its predominant occurrence in  the 
low er and  upper extrem ities, synovial sarcomas may also 
be found in several other body locations such as head, 
neck, and trunk. Based on the histopathological appearance, 
synovial sarcomas can be divided into biphasic, m onophasic 
fibrous, or m onophasic epithelial (very rare), and poorly 
differentiated tum ors [1]. Among several num erical and 
structural cytogenetic abnormalities, also a recurrent translo­
cation betw een the  chromosomes X and 18 (Figure l)  has 
been encountered  [14], A compilation of all cytogenetic 
studies perform ed to date indicates that this t(X;18)(pll,2; 
q ll.2 )  is present in  more than 90% of the synovial sarcomas, 
in  about one th ird  of the cases as the sole cytogenetic 
anomaly [2, 4], The vast majority of primary tumors exhibit 
a  near d ip lo id  karyotype and, compared to locally recur­
ring and m etastatic lesions, are less likely to carry addi­
tional secondary aberrations [15].
Considering a putative causal relationship betw een the 
occurrence of t(X ;18)(p ll.2 ;q ll.2 ) and synovial sarcoma 
developm ent, studies were carried out to characterize the 
chrom osom al breakpoint in  detail and to isolate the genes 
involved. Based on fluorescence in situ hybridization 
(FISH) analysis w ith X chromosome-specific yeast artificial 
chrom osom e (YAC) probes, we and others identified two 
alternative X p ll .2  breakpoints, one within the ornithine 
am inotransferase-like 1 (OATLl) pseudogene cluster and 
another one close to the related OATL2 cluster [16, 17]. 
Accordingly, a subgroup of tumors showed a split fluores­
cent signal w hen hybridized with an OATLl-specific 
YAC, b u t n o t with, an OATL2-specific YAC. The opposite 
was observed in the other subgroup of tumors, indicating 
that the tw o alternative X p ll.2  breakpoints are m utually 
exclusive [18]. The subsequent subcloning of one of the 
YACs [OATLl] resu lted  in  probes that hybridize to altered
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F igu re  1 Partial synovi al s arcoma- derived karyotype sh owing tb e 
normal chromosomes X and 18 and its translocation derivatives X/ 
18 and 18/X.
restriction fragments in  tum or DNAs after Southern blot 
analysis. These probes, in turn, were used to isolate a chi- 
meric breakpoint fragment containing both chromosome 
X and chromosome 18-derived sequences [19, 20], Further 
positional cloning studies led to the isolation of the genes 
that are disrupted in  t(X;18)(pll.2;qll.2)'positive synovial 
sarcomas. It was found that, in  conformity with the previous 
findings, one of these genes (S Y T ; chromosome 18) becomes 
fused to one of two alternative X chromosomal genes 
[SSXl or SSX2) located in the OATL1 and OATL2 regions, 
respectively [21-23].
The normal S Y T  gene transcript (mRNA) measures 
about 4.0 kb (Figure 2) and encodes a 387 amino acid pep­
tide rich in  glutamine, proline, and glycine. The deduced 
protein shows no overt homologies to known protein se­
quences, w ith the exception of three potential SH2 binding 
domains and one potential SH3 binding domain [21]. 
These domains have been implicated in protein-protein in­
teractions related to signal transduction [24]. Recently, the 
mouse homolog of S Y T  was cloned and, through database 
searches, annexin-like sequence repeats (also present in 
hum an SYT] were found which, again, may be involved in 
protein-protein interactions [25]. S Y T  is an ubiquitously 
expressed gene. In the adult mouse, SYT  mRNAs are 
present in several organs, most markedly in  heart, kidney 
and testis. RNA in situ hybridization experiments have 
shown that during mouse embryonic development, SY T  
expression turns from ubiquitous at initial stages into more 
restricted to cartilagineous and specific neuronal cells and 
some epithelial derived tissues, at later stages [25]. The 
SSX l  and SSX2  gene transcripts are approximately 1.6 kb 
long and encode highly homologous proteins (81% identity 
over 188 amino acids) [23]. These proteins are rich in  
charged amino acids, including an acidic C-terminal tail, 
and contain consensus sequences for N-glycosylation and 
tyrosine phosphorylation. Notably, the SSX protein se­
quences contain N -term inal domains which exhibit ex­
tended homologies to the so-called Kruppel-associated 
box (KRAB) originally found in  the Drosophila Kruppel
gene product. KRAB domains have also been found at the 
N -term inal ends of a subgroup of zinc finger proteins and 
are thought to be involved in  transcriptional repression 
[26]. Data base searches revealed that SSX2 is identical to 
a gene (designated HOM-MEL40) that was independently 
isolated by others, based on its abundant expression in 
melanomas [27]. Normally, the S S X  genes exhibit very re­
stricted expression patterns, w ith transcripts mainly in 
hum an testis and thyroid [23]. The SYT-SSX  fusion RNAs 
are about 2.4 kb long (Figure 2) and, in the majority of 
cases, encode proteins in  w hich the last eight amino acids 
of SYT are substituted for the last 78 amino acids of SSX. 
Some rare variants have also been described which carry 
more N-terminally located breakpoints either in SYT or 
SSX [22, 23]. It is noteworthy that all the reported fusion 
transcripts exclude the putative KRAB domain present in 
SSX and at least one of the putative SH2 binding domains 
present in  SYT. It is assumed that these translocation-asso­
ciated ablations have functional implications for the devel­
opment of synovial sarcomas.
The overall uniform ity demonstrated in chimeric tran­
scripts indicates that the chromosomal breakpoints must 
be clustered w ith in  specific introns in the SYT  and SSX 
genes. We have m apped six breakpoints within the SYT 
gene and found that indeed all of them  were located 
w ith in  the same in tron  just upstream  to the exon encoding 
the last eight amino acids (Figure 3). Very similar results 
were obtained by others [23]. Analogous attempts to map 
breakpoints on the X-chromosome were hampered by the 
fact that this region harbors various (low-copy) repetitive 
elements. As a corollary of our ongoing work, we recently 
cloned a novel S S X  gene, designated SSX3 , also located 
on the X-chromosome but apparently not implicated in 
t(X;18)(pll.2;qll,2)-positive synovial sarcomas. In addition, 
we found indications for the existence of at least two more 
SSX-related genes, SSX4 and SSX5, within the same region 
[28]. Also* in  another study, evidence has been provided
F igure  2 Northern blot analysis of three synovial sarcomas (lanes 
1—3) and two normal control tissues (lanes 4 and 5) using a SYT 
cDNA as probe. The positions of the SYT and SYT-SSX mRNAs are 
marked,
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Figure 3 Partial genomic map of the SYT gene and the positions of six synovial sarcoma-a; 
(arrows). The last SYT  exon is marked by 3' end. X = Xbal\ B = BamHI; H = Hindffl) E = EcoRL
for the presence of m ultiple SSX genes in  X p ll .2  [29], 
These observations are in  agreement w ith  the repetitive 
nature  of th is genomic segment.
Some characteristics of the t(X ;18)(pll.2;qll*2) and the 
SYT-SSX fusions are comparable with those pertaining to 
o ther sarcomas, i.e., a w idely expressed gene on one chro­
m osom e becomes juxtaposed to a transcription factor gene 
w ith  a restricted expression pattern on another chromosome, 
resulting  in  a fusion transcript encoding an activator of 
transcrip tion  [30]. Even though SSX  sequences becom e ex­
pressed w hen fused to S Y T  and share some features typical 
of transcription factors, a definite role for the SYT-SSX fu­
sion  proteins in transcriptional control still has to be as­
certained.
Considering that t(X;18)(pll.2;qll.2) is specifically present 
in  synovial sarcomas, its value as a diagnostic m arker seems 
to be unquestionable. The use of YAC probes for FISH analy­
sis on fresh or archival tumor samples has am ply proven its 
usefulness in  the detection of the translocation and the lo ­
calization of the X p ll.2  breakpoints, even w hen  com plex 
rearrangem ents are present [18, 31], In addition, the isola­
tion  and characterization of the SY T  and S S X  genes has 
opened  up  the possibility of employing a reverse tran ­
scrip tion  polymerase chain reaction (RT-PCR) assay as a 
m eans to detect SYT-SSX  fusion transcripts and, therefore, 
to retrieve information from tumors not amenable to cytoge­
n e tic  analysis, By using the RT-PCR approach, SYT-SSX 
transcripts have been detected in 70 synovial sarcomas—45 
w ith  SYT-SSX1  transcripts and 25 w ith S Y T -S S X 2 tran­
scrip ts [22, 23, 32, 33], Both techniques, FISH and RT- 
PCR, have also been used to evaluate a possible correlation 
between X p ll.2  breakpoint localization and histological tu ­
m or (sub) type. Interestingly we found that all b iphasic 
synovial sarcomas exhibited a break in the OATLl [SSXÍ] 
region, whereas most tumors diagnosed as m onophasic 
w ere  found to carry a break in  the OATL2 (SSX2) region 
[18, 34]. These latter findings have been corroborated by 
som e but not all reports from other investigators and, as 
such, m ust await further validation [32, 33, 35].
RECURRENT D N A  ALTERATIONS IN BONE AND SOFT 
TISSUE TUM ORS REVEALED BY COMPARATIVE 
GENOMIC HYBRIDIZATION
O verexpression of cellular oncogenes may affect tum or 
growth. Such an overexpression can be brought about by 
various m echanism s, including gene amplification [36]. In 
bone and soft tissue tumors w ith  complex karyotypes (Figure 
4) am plification of, e.g., the M Y C  oncogene on  chromo­
some 8q has repeatedly been reported [37,38], Also, putative 
oncogenes in  die chromosome 12ql3-ql4 region, including 
MDM2 , CDK4 and  SAS, w ere found to be amplified in  a
F ig u re  4 Partial metaphase spread of a soft tissue tumor (malig­
nant fibrous histiocytoma) showing supernumerary ring chromo' 
som.es (arrows).
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substantial num ber of cases [39-41]. Since MDM2 appears 
to inactivate the tumor suppressor TP53, a growth advantage 
via 12ql3-~ql4 amplification has been attributed to increased 
copy num bers and expression levels of the MDM2 gene 
[39, 42]. In osteosarcomas, MDM2 amplifications have 
been detected specifically in  recurrent and metastatic 
lesions, and it has been suggested that such amplifications 
may be associated w ith a poor prognosis [43]. Other genomic 
alterations include loss or rearrangement of the chromosome 
13ql4 and 17pl3 subregions harboring the RBI and TP 5 3 
tum or suppressor genes, respectively [44-48], It has been 
show n that alterations at the RBI locus in primary 
osteosarcomas may serve as indicators for a poor clinical 
outcome [49].
In order to get further insight into the molecular cytoge­
netic changes that are relevant for tumor growth, the recently 
developed comparative genomic hybridization (CGH) tech­
nique [50-52] was employed to map regions of amplification 
in  a large group of bone and soft tissue tumors of various 
histologic (sub) types. The CGH technique provides informa­
tion not only on the overall ocurrence of amplifications, 
but also on the extent of the regions affected [51, 53-55], 
The results obtained are instrumental in the ultimate identi­
fication and isolation of the genes involved.
Through CGH, DNA amplifications were detected in 
different soft tissue tumors, including fibrosarcomas, liposar­
comas, leiomyosarcomas, and malignant fibrous histiocyto­
mas [52, 56, unpublished results]. The sizes of the 
amplified regions varied considerably, as did the number 
of am plified regions detected in each individual tumor 
sample. In total, 14/60 soft tissue tumors showed amplifica­
tions at 12ql4. In some cases the amplicons included, be­
sides 12ql4, parts of 12ql3 or 12ql5. Also, other regions 
of chromosome 12 were amplified, although less fre­
quently [52]. Amplicons covering 12q21-q22 were de­
tected in four cases and amplification of the 12q24 segment 
was detected in  two cases. A specific region on the long 
arm of chromosome 1 also showed frequent increases in 
sequence copy numbers, Although the different amplicons 
coinciding w ithin this region were variable in size, they 
showed a minimal overlap at Iq21-q22. Amplification of 
this segment was observed at least as frequently as the 
12ql4 amplification. In addition, the occurrence of the 
Iq21-q22 and 12ql4 amplicons appeared to be unevenly 
distributed among the different soft tissue tumor subtypes. 
However, no clear correlation between the presence of either 
Iq21-q22, 12ql4, or both amplicons and any of the cur­
rently known clinical parameters has been observed. There­
fore, it remains to be established what the biological 
consequences of the various combinations may be. In total, 
amplifications involving 25 different chromosomal (sub) 
regions were observed in  the soft tissue tumors studied.
In 5/20 osteosarcomas, CGH revealed gain of whole 
chromosomes or chromosome arms, and in three of these 
cases, 6p was involved. Regional copy number increases 
were repeatedly seen at lq , 8q and 17p [57, unpublished 
results]. Again, the lq  amplicons were variable in  size, bu t 
show ed a m inim al region of overlap at Iq21-q23 (three 
cases). Overrepresentation of 8q23-qter, a region in which 
the M YC  gene maps, was observed in  4 cases, including
one that showed gain of the whole 8q arm. Amplifications 
of the 1 7 p ll-p l2  region (Figure 5) were detected in five 
cases, including one involving the whole I7p arm. Overall, 
CGH analysis revealed high-level DNA amplifications at 
23 different chromosomal sites in  primary as well as meta­
static osteosarcomas.
The majority of the bone and soft tissue tumors men­
tioned above w ere also assayed by Southern blot analysis 
for amplifications of the 12ql4-linked proto-oncogenes 
MDM2, CDK4, SAS, CHOP, GLI and A2MR [39, 58, 59]. 
CGH analyses revealed increased DNA-sequence copy 
numbers in all the cases w ith known gene amplifications, 
as expected. Also, in a few cases without known gene ampli­
fications, 12ql4 amplicons were detected. A role as a selec­
tive driver in these amplicons was previously assigned to the 
MDM2 or CDK4 genes [39, 40, 58, 60], However, the CGH 
results suggest that also alternative explanations should be 
considered, including amplification via a mechanism driven 
by another gene(s) located in band 12ql4 [61, 62].
CGH analysis revealed two novel major regions of ampli­
fication, nam ely Iq21-q22 and 17pll-12. Increased se­
quence copy numbers coinciding with the Iq21-q22 
segment were observed in 14 soft tissue tumors and four os­
teosarcomas. So far, this amplification was not observed in 
other malignancies such as prostate cancer or malignant
Figure 5 Comparative genomic hybridization analysis (upper 
panel) and fluorescence intensity profiles (lower panel) of an 
osteosarcoma exhibiting a 17pll-pl2 amplicon. Tumor DNA was 
labeled in red and normal DNA in green. The chromosomes were 
counterstained using DAPI. The CGH ratio profile is marked in blue.
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glioma [53, 63], nor has it previously been associated w ith  
the development of hum an sarcomas. Conceivably, the 
Iq21-q22 region may harbor a gene(s) important for hum an 
bone and soft tissue tumor initiation and/or progression. 
Several candidate genes have been mapped to this region, 
including the octamere-binding transcription factor OTFl 
(Iq22-q25) and various members of the S i00 family of cal­
cium-binding proteins, e.g., CACY  and CAPL (Iq21-q25) 
[64, 65], Overexpression of the CACY  gene has been associ­
ated w ith metastatic behavior of hum an melanomas [66], 
High level amplifications at 17pll~pl2  were detected in 
five out of 20 osteosarcomas. Very sim ilar results w ere re ­
cently reported by Tarkkanen et al. [67], This same region 
was found to be affected only sporadically in m alignant as­
trocytomas [68; Hulsebos, personal communication] and  in 
one of the soft tissue tumors that we tested [52, 56], render­
ing this anomaly into a highly specific one for osteosarco­
mas. So far, the 1 7 p ll-p l2  segment does not seem to harbor 
any obvious candidate gene(s). Future positional cloning 
studies should be aimed at the identification of the genes re» 
lated to cancer development within these regions.
Although the CGH technique is very well suited for the 
detection and mapping of DNA-sequence copy num ber 
changes, especially amplifications, one should be aware of 
its limitations. For example, CGH may fail to detect low-level 
copy num ber changes. Also, the total length of am plified 
DNA has to be of a certain size in order to be detectable 
[51, and references therein]. Thus, the actual am plification 
frequencies may be significantly higher than provided 
here, especially for the smaller amplicons. A more complete 
overview of genetic alterations in a given series of tum ors 
can be obtained by combining CGH w ith FISH and other 
molecular genetic techniques using probes that specifically 
target the genomic regions highlighted by CGH.
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